Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients (Q42977950)

12 November 2017

title

Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients (English)

1 reference

12 November 2017

0 references

1 reference

3

Marilyn M Wagener

1 reference

12 November 2017

4

Nina Singh

1 reference

12 November 2017

Hsin-Yun Sun

1

1 reference

12 November 2017

Thomas V Cacciarelli

series ordinal

2

1 reference

12 November 2017

publication date

4 July 2010

1 reference

12 November 2017

published in

Transplant Immunology

1 reference

12 November 2017

volume

23

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

166-169

1 reference

Cytomegalovirus infection following liver transplantation: review of the literature

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Real-time PCR assay compared with antigenemia assay for detecting cytomegalovirus infection in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Definitions of cytomegalovirus infection and disease in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Impact of pretransplant infections on clinical outcomes of liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV infection in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

CDC definitions for nosocomial infections, 1988

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.TRIM.2010.06.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRIM.2010.06.013

1 reference

12 November 2017

1 reference